Engineers Gate Manager’s Immuneering IMRX Stock Holding History

Engineers Gate Manager’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,607	Closed	-$16.1K	–	2335
2025 Q1	$16.1K	Buy	+10,607	New	+$19.3K	﹤0.01%	2089

Other funds holding IMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Engineers Gate Manager's IMRX Position: Q2 2025 in Review

Engineers Gate Manager sold out of Immuneering (IMRX) in Q2 2025, closing a stake of 10,607 shares — an estimated $16.1K sold.

Engineers Gate Manager first reported a position in IMRX in Q1 2025 and held it in 1 quarter. The position peaked at $16.1K in Q1 2025. 39 funds tracked by Wall St. Rank hold IMRX as of Q2 2025.

Engineers Gate Manager reported no remaining Immuneering position as of Q2 2025 after selling out during the quarter.
Engineers Gate Manager sold 10,607 Immuneering shares in Q2 2025, an estimated $16.1K.
Engineers Gate Manager first reported a position in Immuneering in Q1 2025 and held it in 1 quarter.
Engineers Gate Manager's Immuneering position peaked at $16.1K in Q1 2025.
39 funds tracked by Wall St. Rank held Immuneering as of Q2 2025.

Based on Engineers Gate Manager's 13F filing for Q2 2025, filed 14 Aug 2025.